MILWAUKEE, WI (May 1, 2008) – Prodesse, Inc. today announced the selection of its clinical trial sites for ProGastro Cd. ProGastro Cd is a real time PCR assay for the rapid detection of toxigenic strains of Clostridium difficile. This is Prodesse’s first enteric product to begin the FDA clearance process and the third product to undergo clinical trials for FDA clearance. The company’s flagship ProFlu+™ product received FDA 510(k) clearance on January 4, 2008; its Pro hMPV+™ product has completed clinical trials and will be submitted to the FDA in early fall. Overall, Prodesse plans to conduct clinical trials at 12 sites in 2008.
